131I-IMAZA is developed at the University of Wurzburg, Germany, together with its diagnostic analogue 123I-IMAZA as improved CYP11B ligand targeting molecules and compared to the reference product 123I/131I-IMTO. 131I-IMAZA binds to the enzymes CYP11B1 and CYP11B2 (which are expressed exclusively in the adrenal cortex and therefore, represent suitable targets for a specific imaging technique, and subsequent therapeutic effect. First clinical trials showed improvement in a patient with rapidly progressing adrenocortical carcinoma (ACC).
Target/Mechanism: Adrenergic tissues
Radiation Type: beta electrons (β–)